The leptospirosis market is primarily driven by growing incidences of the disease. According to WHO, there are an estimated 1.03 million cases of leptospirosis annually worldwide, with 58,900 deaths. Tropical countries report the highest incidences. The disease is closely linked to poor sanitation and flooding. With changing climate and prevalence of slums in developing regions, cases are on the rise. Additionally, lack of awareness about the disease is another factor contributing to the market growth. The market is also witnessing increasing adoption of diagnostic kits for faster detection of the disease. Technological advancements are leading to development of more accurate and easy-to-use diagnostic kits such as immunochromatographic tests which provide results in 15-30 minutes. Rising healthcare expenditure in developing countries will further aid market expansion during the forecast period.
The Global Leptospirosis Market Size is expected to witness high growth, exhibiting CAGR of 5.8% over the forecast period, due to increasing prevalence of leptospirosis infections globally. According to the World Health Organization (WHO), leptospirosis contributes to over 1 million cases of severe illness and approximately 60,000 deaths worldwide annually.
Key players operating in the leptospirosis market are USAntibiotics, Dr. Reddy's Laboratories Ltd., Century Pharmaceuticals Ltd., Mayne Pharma Group Limited, Sun Pharmaceutical Industries, Inc., Ralington Pharma, F. Hoffmann-La Roche Ltd, Pfizer Inc., Sandoz International GmbH, ISKON REMEDIES & GMT, Haustus Biotech Pvt. Ltd., and Aden Healthcare. These key players are focusing on new product launches, collaborations and acquisitions to strengthen their market position and to cater growing needs of the leptospirosis patients worldwide.
Read more
https://healthcarelatesteditionnews.blogspot.com/2023/11/leptospirosis-is-estimated-to-witness.html
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Russian
Romaian